Engineering antibodies for clinical applications.
Molecular engineering has contributed immensely to the clinical success of antibodies in recent years. The modular structure of antibodies has permitted their modification in numerous ways, to meet various clinical requirements. With the help of antibody engineering, it has been possible to modify the molecular size, pharmacokinetics, immunogenicity, binding affinity, specificity and effector function of antibodies. In addition, fusion proteins of antibodies with various proteins and peptides have yielded targeted biological modifiers, toxins and imaging agents. This review focuses on the recent trends in antibody engineering for improving their clinical utility.
Jain
Maneesh
M
Department of Biochemistry and Molecular Biology, Department of Pathology and Microbiology, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA.
Kamal
Neel
N
Batra
Surinder K
SK
D000818:Animals; D000906:Antibodies / Q000235:genetics* / Q000276:immunology / Q000627:therapeutic use*; D001666:Binding Sites, Antibody; D020650:Combinatorial Chemistry Techniques; D016503:Drug Delivery Systems / Q000379:methods; D015195:Drug Design; D006801:Humans; D015202:Protein Engineering
D000906:Antibodies